Tesamorelin: research overview

The short version

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). It is the only peptide on this desk with a specific, well-documented regulatory approval: the US FDA approved it in 2010 to reduce excess abdominal fat in HIV-infected patients with lipodystrophy — a body-composition disorder caused by certain antiretroviral medications ^[2].

What it does in that approved setting is reasonably clear: it stimulates the pituitary to produce more growth hormone (GH), which drives fat loss from the visceral depot (around the internal organs). A 2026 pooled analysis of five RCTs confirmed reductions in visceral adipose tissue averaging nearly 28 cm² ^[1]. That approval does not extend to general belly-fat reduction, anti-aging, or cognitive enhancement — those uses are off-label and lack large controlled trials in non-HIV populations ^[7].

Tesamorelin is WADA-prohibited in sport as a GHRH analogue. Research-grade material carries no pharmaceutical-quality guarantees.

What it is

Tesamorelin is a 44-amino-acid synthetic GHRH analogue — specifically, the sequence GHRH(1-44)-NH2 with a trans-3-hexenoic acid group attached to the N-terminus. That N-terminal modification is the structural key to its clinical utility: it makes the peptide resistant to cleavage by dipeptidyl peptidase-IV (DPP-IV), an enzyme that rapidly degrades native GHRH in plasma. The result is meaningfully longer activity in circulation relative to the endogenous hormone.

The compound is supplied as an acetate salt and administered by subcutaneous injection. It is not orally bioavailable in any established formulation. Its drug classification is growth hormone-releasing hormone receptor (GHRH-R) agonist.

How it works

Tesamorelin binds the GHRH receptor on somatotroph cells in the anterior pituitary, activating a Gs/adenylyl-cyclase/cAMP/PKA signaling cascade that drives GH synthesis and secretion. The GH released in turn signals the liver to produce insulin-like growth factor-1 (IGF-1), and both GH and IGF-1 promote lipolysis preferentially in visceral adipose tissue.

A pharmacologically important distinction: tesamorelin amplifies the body's own pulsatile GH rhythm rather than supplying exogenous GH directly. Its metabolic and safety profile therefore differs from recombinant human GH, though the downstream hormonal targets overlap. In a study of 13 healthy men, two weeks of tesamorelin increased mean overnight GH by 0.5 µg/L and raised IGF-1 by 181 µg/L without significantly affecting fasting glucose or insulin-stimulated glucose uptake ^[4] — though this was a very small sample over a short period.

Mechanism targets include: anterior-pituitary somatotrophs (via GHRH-R), visceral adipose tissue (lipolysis), liver (IGF-1 synthesis), and the broader GH/IGF-1 axis.

What the research shows

The clinical evidence is concentrated in HIV-positive adults on antiretroviral therapy — that is the population in which every large controlled trial was conducted, and it matters for interpreting the findings.

Core approval data: The pivotal 26-week phase-3 RCT (n=412 HIV patients) showed tesamorelin 2 mg/day reduced visceral adipose tissue by 15.2% versus a 5.0% increase in the placebo group; serum triglycerides fell by 50 mg/dL versus a 9 mg/dL rise with placebo, and IGF-1 increased by 81.0% ^[6]. A 52-week extension (n=273 tesamorelin, n=137 placebo) showed sustained VAT reduction of approximately 18% at 52 weeks; visceral fat reaccumulated after discontinuation, and glucose changes were not clinically significant over the study period ^[5].

Liver fat: A 6-month JAMA RCT (n=50) found tesamorelin produced a treatment effect of −42 cm² in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net −2.9% (P=0.003) ^[3].

2026 meta-analysis: Pooling five RCTs in HIV-associated lipodystrophy, the most recent synthesis found VAT reductions averaging −27.71 cm² (95% CI −38.37 to −17.06; P<0.001), trunk-fat reduction of −1.18 kg, hepatic-fat fraction reduction of −4.28%, and lean-mass increase of +1.42 kg — all without serious adverse events ^[1].

Evidence quality caveats: All large RCTs were in HIV-positive adults on antiretroviral therapy. Mechanistic plausibility exists for non-HIV applications (visceral-fat reduction is a GH/IGF-1 axis effect, not inherently HIV-specific), but no large RCTs have been conducted in general populations. The NIH LiverTox monograph assigns tesamorelin a liver-injury likelihood score of E — unlikely hepatotoxin, no attributed liver-injury cases ^[2].

A 2026 narrative review of injectable peptides in sports medicine classified tesamorelin among investigational GH-axis secretagogues with 'uncertain safety profiles' in non-approved contexts ^[7].

Reported effects, cautions, and safety

Regulatory and labeled cautions: Active malignancy is a labeled contraindication; tesamorelin raises IGF-1, a growth factor, and 52-week trials showed no excess malignancy signal, but long-term oncologic-safety data are limited ^[5]. GH-axis stimulation can cause modest glucose perturbation; monitoring is warranted in prediabetic individuals, though a dedicated diabetes-adjacent trial found no significant HbA1c change ^[5]. Visceral fat reaccumulates within weeks of discontinuation — benefits are contingent on continued administration ^[5].

Off-label and investigational concerns: Cognitive findings are mixed: one non-HIV aging trial suggested executive-function benefit; a 2025 HIV cognition trial did not show significant neurocognitive improvement over standard care. Neither result should be treated as settled. All uses outside HIV-associated lipodystrophy are off-label ^[7].

WADA status: Tesamorelin is prohibited in sport under WADA category S2 (peptide hormones, growth factors, related substances and mimetics) as a GHRH analogue, both in- and out-of-competition.

Research-grade supply caveat: Research-grade tesamorelin is supplied for laboratory use and lacks the purity, potency, and sterility oversight of the approved prescription product. The approved product requires a prescription for its specific HIV indication; all other use falls outside any approved framework.

Note: this page does not list a dose. Doses in the trials cited above are reported as study-design details attributed to the study, not as recommendations.

Where it fits on this desk

Among the four peptides on this desk, tesamorelin occupies the clearest regulatory position — but also the narrowest one. Its FDA approval is real and specific, its phase-3 data are solid within their studied population, and its mechanism is well understood. The temptation to extrapolate from that evidence to a broader anti-aging or body-recomposition use is understandable and mechanistically plausible, but 'mechanistically plausible' and 'established by controlled evidence' are different things. The literature is honest about this gap ^[7], and so is this desk.